Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can scans and DNA predict cancer treatment success?

NCT ID NCT07259915

Knowledge-focused Sponsor: Centre Henri Becquerel Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aims to better predict how head and neck cancer responds to chemoradiotherapy. Researchers will use MRI, PET/CT scans, and blood/tumor DNA tests from 152 patients to build a combined prediction model. The goal is to identify which patients have a complete response within 12 months after treatment, potentially personalizing future care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors predict which patients will benefit from chemoradiotherapy, potentially avoiding ineffective treatments and their side effects.
What could go wrong
This is an observational study, not a treatment trial. It may not lead to a direct benefit for participants, and the prediction model might not be accurate enough for routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 152 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2025

An estimate. Start dates often move.

Expected to finish

Aug 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient with squamous cell carcinoma of the oropharynx (cT2-cT4) or squamous cell carcinoma of the oral cavity (cT2-cT4) * With lymph node involvement (cN1, cN2, or cN3) (confirmation of lymph node involvement after review of imaging in CCP and without histological confirmation required) * Eligible for curative treatment with cisplatin-based chemoradiotherapy alone (100 mg/m2 every 3 weeks or 40 mg/m2 weekly) * Regardless of p16 status * Affiliated with or covered by a social security system Exclusion Criteria: * Head and neck squamous cell carcinomas in other locations (salivary gland, larynx, hypopharynx, cavum, sinuses) * Primary squamous cell carcinoma of the lymph nodes * History of radiotherapy to the head and neck region * Radiochemotherapy not based on the use of cisplatin * Pregnant or breastfeeding women * History of invasive cancer in the last 3 years (except for Breslow melanoma less than 1 mm) * Contraindication to MRI, CT, or PET/CT * Allergy or contraindication to iodine, gadolinium, or 18F-FDG * Uncontrolled diabetes (fasting blood glucose greater than 12 mmol/l) * Patients unable to understand the study for any reason or to comply with the trial requirements (language, psychological, geographical issues, etc.) * Patients under guardianship or conservatorship * Patients deprived of their liberty by judicial or administrative decision * Patients undergoing psychiatric care that renders them incapable of giving their consent * Patients admitted to a health or social care facility for purposes other than research

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Squamous cell cancer of head and neck (SCCHN) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma oral cavity squamous cell carcinoma oropharynx squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Squamous cell cancer of head and neck (SCCHN)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Henri Becquerel

    Rouen, France

  • Centre Hospitalier Universitaire

    Rouen, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.